You are here
Media Advisory
Tuesday, August 15, 2017
NIH herpesvirus study in mice leads to discovery of potential broad-spectrum antiviral
What
After herpesviruses infect a cell, their genomes are assembled into specialized protein structures called nucleosomes. Many cellular enzyme complexes can modulate these structures to either promote or inhibit the progression of infection. Scientists studying how one of these complexes (EZH2/1) regulated herpes simplex virus (HSV) infection unexpectedly found that inhibiting EZH2/1 suppressed viral infection. The research group, from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, then demonstrated that EZH2/1 inhibitors also enhanced the cellular antiviral response in cultured cells and in mice.
Once a person has been infected with a herpesvirus, the virus persists in a latent form, sometimes reactivating to cause recurrent disease. Two-thirds of the global population are infected with HSV-1, and at least 500 million are infected with HSV-2, according to the World Health Organization. These viruses cause a range of diseases and conditions from oral cold sores to genital lesions to serious eye infections that can lead to blindness. In infants who acquire the infection from their mothers, HSV can cause neurological and developmental problems. People infected with HSV also have an enhanced risk of acquiring or transmitting human immunodeficiency virus (HIV). Treatment usually involves antiviral drugs that interfere with viral replication, but new approaches to combat these infections are needed.
The NIAID group demonstrated that EZH2/1 inhibitors not only suppressed HSV infection, spread, and reactivation in mice, but also suppressed human cytomegalovirus, adenovirus, and Zika virus infections in cell culture using human primary fibroblast cell lines. These authors suggest that EZH2/1 inhibitors have considerable potential as broad-spectrum antivirals.
Article
J. Arbuckle, et al. Inhibitors of the histone methyltransferases EZH2/1 induce a potent antiviral state and suppress infection by diverse viral pathogens. mBio. DOI: 10.1128/mBio.01141-17 (2017).
Who
Thomas M. Kristie, Ph.D., Chief of the Molecular Genetics Section of NIAID’s Laboratory of Viral Diseases, is available to comment on this study.
Contact
To schedule interviews, please contact Ken Pekoc, 301-402-1663, kpekoc@niaid.nih.gov(link sends e-mail).
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®